INO-4800

Overview

INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells. Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry. A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers	2022/06/24	NCT05430958	Phase 1	Withdrawn	Inovio Pharmaceuticals
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure	2020/11/24	NCT04642638	Phase 2	Terminated	Inovio Pharmaceuticals
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers	2020/04/07	NCT04336410	Phase 1	Completed	Inovio Pharmaceuticals

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

COVID-19 Vaccine Landscape: mRNA and DNA Vaccine Efficacy and Development

2 years ago

• mRNA vaccines like Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273 have demonstrated high efficacy (72-95%) against moderate-to-severe COVID-19 in adults, with ongoing studies evaluating their effectiveness against emerging variants. • DNA vaccines, including Zydus Cadila's ZyCov-D, have shown promise with good safety profiles and the ability to induce neutralizing antibodies and cellular immune responses, offering a cost-effective alternative, especially in developing countries. • Studies indicate that extending the interval between doses of mRNA vaccines may enhance immune responses, particularly in previously uninfected individuals, although the recognition of variants like Omicron may decline more rapidly. • Booster doses of mRNA vaccines, such as BNT162b2, have been shown to significantly improve neutralizing titers against Omicron variants, supporting a three-dose regimen for enhanced protection.

Former GSK CEO Sir Andrew Witty Appointed to Lead WHO's Global COVID-19 Vaccine Initiative

5 years ago

• Sir Andrew Witty, former GlaxoSmithKline CEO, takes temporary leave from UnitedHealth's Optum to spearhead WHO's COVID-19 vaccine development efforts starting next week. • Over 70 COVID-19 vaccine candidates are in development globally, with three frontrunners from CanSino Bio, Moderna, and Inovio already advancing to clinical testing phases. • The appointment comes at a critical time as WHO faces funding challenges, with the Gates Foundation pledging $150 million following US funding withdrawal.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access